依维莫司抑制mTOR对STEMI患者梗死面积的影响:CLEVER-ACS试验
CLEVER-ACS是一项随机、多中心、国际、双盲、安慰剂对照试验,纳入150例接受直接PCI的STEMI患者,随机接受口服依维莫司(第1-3天每日7.5 mg,第4-5天每日5.0 mg)或安慰剂共5天。主要终点为心肌梗死面积变化,结果显示依维莫司组与安慰剂组从基线至30天的心肌梗死面积变化分别为-14.2 g(95%CI:-17.4至-11.1 g)和-12.3 g(95%CI:-16.0至-8.7 g),P=0.99;微血管阻塞变化分别为-4.8 g(95%CI:-6.7至-2.9 g)和-6.3 g(95%CI:-8.7至-4.0 g),P=0.14。结论认为早期mTOR抑制未能减少30天心肌梗死面积或微血管阻塞,不良事件两组无差异。
要点
- STEMI直接PCI后早期口服依维莫司5天未减少30天心肌梗死面积(P=0.99)。
- 依维莫司未显著改善30天微血管阻塞(P=0.14)。
- 两组不良事件无差异。
核心结论
- 在接受PCI的STEMI患者中,早期使用依维莫司抑制mTOR未能减少30天心肌梗死面积或微血管阻塞。
研究设计与样本
- CLEVER-ACS为随机、多中心、国际、双盲、安慰剂对照试验,共纳入150例接受PCI的STEMI患者。
- 患者随机接受口服依维莫司(第1-3天每日7.5 mg,第4-5天每日5.0 mg)或安慰剂共5天。
主要发现
- 从基线至30天心肌梗死面积变化:依维莫司组-14.2 g(95%CI:-17.4至-11.1 g),安慰剂组-12.3 g(95%CI:-16.0至-8.7 g),P=0.99。
- 从基线至30天微血管阻塞变化:依维莫司组-4.8 g(95%CI:-6.7至-2.9 g),安慰剂组-6.3 g(95%CI:-8.7至-4.0 g),P=0.14。
- 不良事件在研究组间无差异。
关键数值与推荐
- 主要终点为心肌梗死面积变化,次要终点为微血管阻塞变化,均以心脏磁共振评估。
- 依维莫司给药方案:第1-3天每日7.5 mg,第4-5天每日5.0 mg,共5天。
临床怎么用
- 对于接受PCI的STEMI患者,不推荐以依维莫司抑制mTOR作为减少梗死面积或微血管阻塞的常规策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early inflammation following acute ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) affects myocardial infarct (MI) size and left ventricular remodeling. The mammalian target of rapamycin (mTOR) is involved in the enhanced inflammatory response and its inhibition has exerted beneficial effects on MI size in preclinical models of acute MI. OBJECTIVES: The CLEVER-ACS (Controlled Level Everolimus in Acute Coronary Syndromes) trial evaluated the effects of targeting inflammation by mTOR inhibition in patients with STEMI undergoing PCI. METHODS: CLEVER-ACS was a randomized, multicenter, international, double-blind, placebo-controlled trial. A total of 150 patients with STEMI undergoing PCI were randomly assigned to oral everolimus (days 1-3: 7.5 mg daily; days 4-5: 5.0 mg daily) or placebo for 5 days. The primary endpoint was the change in MI size. The secondary endpoint was the change in microvascular obstruction (MVO) from baseline (12 hours to 5 days after PCI) to 30 days as assessed by cardiac magnetic resonance imaging. RESULTS: The changes in MI size from baseline to 30 days, the primary endpoint, were -14.2 g (95% CI: -17.4 to -11.1 g) and -12.3 g (95% CI: -16.0 to -8.7 g) in the everolimus and placebo groups (P = 0.99). Corresponding changes in MVO were -4.8 g (95% CI: -6.7 to -2.9 g) and -6.3 g (95% CI: -8.7 to -4.0 g) in the everolimus and placebo groups (P = 0.14). Adverse events did not differ between the study groups. CONCLUSIONS: Among STEMI patients undergoing PCI, early mTOR inhibition with everolimus did not reduce MI size or MVO at 30 days. (CLEVER-ACS [Controlled Level Everolimus in Acute Coronary Syndromes; NCT01529554).
引用
- Stähli, Klingenberg, Heg, et al. Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2022. PMID: 36049557. doi:10.1016/j.jacc.2022.08.747
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。